UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
_______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
On August 8, 2022, Standard BioTools Inc. (the “Company”) issued a press release reporting its financial results for the second fiscal quarter of 2022. A copy of the press release is furnished herewith as Exhibit 99.1.
The foregoing information in this Current Report on Form 8-K, including exhibit 99.1 attached hereto, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and shall not be incorporated by reference in any filing under the Securities Exchange Act of 1934, as amended, or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such future filing.
On August 8, 2022, Standard BioTools Inc., (the “Company”) announced a restructuring plan, including a reduction in force. In addition to the reduction in force, the Company will also seek to reduce leased office space and other operating expenses. The purpose of the restructuring plan is to improve operational efficiency and operating costs and better align the Company’s workforce with the current needs of its business.
The Company currently expects cash expenses related to the reduction in force, consisting primarily of severance and termination benefits and related costs, to be in the range of $3 million to $5 million. At this time, the Company is not able, in good faith, to make a determination of the estimated amount or range of amounts to be incurred for every major type of restructuring cost, including the leased office space reduction charges. The Company will file an amendment to this report upon the determination of such amounts. The Company expects to recognize the restructuring costs over the next four quarters. These estimates are subject to a number of assumptions, and actual results may differ.
This Item 2.05 contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements related to the expected costs associated with restructuring plan and expected reductions of operating expenses. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to cost reduction efforts. In addition, the Company’s restructuring costs may be greater than anticipated and the workforce and operating expense reductions may have an adverse impact on the Company’s sales and development activities. Additionally, these forward-looking statements should be considered in conjunction with the cautionary statements and risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and its other filings filed from time to time with the Securities and Exchange Commission. The Company does not assume any obligation to update any forward-looking statement, except as required by law.
(d) Exhibits.
| Exhibit No. | Description | |
| 99.1 | Standard BioTools Inc. Press Release dated August 8, 2022. | |
| 104 | Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Standard BioTools Inc. | ||
| Date: August 8, 2022 | By: | /s/ Vikram Jog |
| Vikram Jog | ||
| Chief Financial Officer | ||
EXHIBIT 99.1
Standard BioTools Announces Second Quarter 2022 Financial Results and Provides Strategic Update
Second quarter revenue of $18.8 million
Completed $250 million strategic cash infusion from Casdin Capital and Viking Global
Upgraded management team and added board members to bring significant sector and operational expertise to the company
Commenced restructuring program with the explicit goal of returning core business to growth, raising gross margins by approximately 7-10% and substantially reducing operating cash burn
Cash, cash equivalents, and short-term investments expected to provide sufficient runway to generate positive free cash flow by end of 2024 while allowing for strategic M&A
Company to host conference call and webcast today at 4:30 p.m. ET
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced financial results for the second quarter ended June 30, 2022.
“Four months after I joined the company as President and CEO, and now with a strategic review process completed, the potential to build a next-generation consolidated life science company around this portfolio of powerful technologies remains incredibly exciting,” said Michael Egholm, PhD, Chief Executive Officer and President of Standard BioTools™. “There is work to do to make this vision a reality, and while it will take time, we are confident we will get there.
“First, we are putting into motion a restructuring plan to return to steady growth across our organization, including improved product positioning and a new disciplined sales execution. This quarter’s results are not the standard we hold ourselves to and we can and will do better in coming quarters and years.
“Second, our plan has us leaning in on operations, assembling a world-class team of seasoned operators, and systematically rolling out our Standard BioTools Business System (SBS) approach. Through these initiatives, we have identified numerous opportunities for gross margin improvements, which we expect will yield an increase of approximately 7-10% by year end 2023.”
Continued Egholm, “I am committed as a leader and on the long-term vision, and we will drive our core business toward profitability while keeping capital available for portfolio expansion through strategic M&A. There is a deep funnel of opportunities, and we believe those will fuel longer-term growth. We look forward to providing updates as we come closer to realizing the vision of Standard BioTools to become a leading solutions partner for the life science industry, offering an innovative portfolio of high-quality, impactful technologies.”
Second Quarter 2022 and Recent Strategic Updates
Phased Restructuring
A phased restructuring plan is underway that we expect will significantly lower operating cash burn beginning in the second half of 2022. With these actions and current cash, cash equivalents, and short-term investments, Standard BioTools expects its cash runway to be sufficient to fund current operations to cash flow breakeven by the end of 2024 while allowing for strategic M&A. As part of the restructuring, the following steps are being taken:
- Right-Sizing General and Administrative Expenses: The company plans to significantly lower general and administrative spend through a reduction in headcount and a decrease in office space to better align with its streamlined operations. Specifically, the company plans to reduce its real estate footprint including its headquarters location in South San Francisco while fostering remote work for certain employees. Beyond these near-term initiatives, the company will pursue continued process optimization through a focused SBS-based approach that may result in additional cost savings and will direct resources into areas with the highest impact on the business.
- Right-Sizing Microfluidics Business: The company will significantly reduce investment in research and development and marketing for the microfluidics business while narrowing its commercial focus to high-value niche markets for specialized applications for which the platform is ideally suited. In addition, the company plans to pursue additional OEM opportunities, similar to its relationship with Olink Holding AB, as a lower-cost and more efficient go-to-market approach.
- Portfolio Rationalization: As part of implementing rigorous portfolio management, the company is rationalizing its expansive product portfolio by exiting its laser capture microdissection and Flow Conductor™ product lines, while de-emphasizing its diagnostics/COVID-19 product line. Revenues from these product lines are not significant.
Corporate Highlights
- Top-grade new management team members with significant sector and operator experience added since capital infusion closed, including Michael Egholm as Chief Executive Officer and President; Alex Kim as Chief Operating Officer; Jeremy Davis as Chief Commercial Officer; Mona Abou-Sayed as Senior Vice President of SBS; Anders Davas as Senior Vice President, Global Operations; and, more recently, Matt Ritchie as Vice President, Global Sales Operations; Seiya Ohta as Vice President, Customer & User Experience; David Panzarella as Vice President, Commercial Operations – Americas; and Kathy Harrell as Vice President and Controller.
- Highly experienced new board members with life sciences and capital markets expertise appointed, including Martin Madaus, PhD, Frank Witney, PhD, and Eli Casdin.
- Closed $250 million strategic capital infusion from leading life science investors Casdin Capital, LLC, and Viking Global Investors LP on April 4, 2022.
Second Quarter 2022 Financial Results
Total revenue was $18.8 million for the quarter ended June 30, 2022, compared with $31.0 million for the second quarter of 2021, driven by lower instrument and COVID-19 testing revenue. Base product and service revenue (excluding COVID-19 testing revenue) was $17.5 million, approximately 35% lower compared with $26.9 million for the second quarter of 2021.
GAAP net loss for the quarter ended June 30, 2022, was $63.5 million, compared with a GAAP net loss of $17.1 million for the second quarter of 2021. The year-over-year increase in GAAP net loss was driven by increases in fair value of the forward sale contract related to the Series B Preferred Stock and bridge loans aggregating $25.4 million, lower revenue, lower product and service margin, and higher operating expenses. Product line exits during the quarter negatively affected product and service gross profit and net loss by $4.7 million and $8.2 million, respectively.
Non-GAAP net loss, which excludes the fair value increases noted above, stock-based compensation, depreciation and amortization expenses, and interest expense, was $25.8 million for the quarter, compared with a non-GAAP net loss of $9.3 million for the second quarter of 2021.
Cash, cash equivalents and short-term investments as of June 30, 2022, were $211.2 million, compared with $30.0 million as of March 31, 2022.
Conference Call Information
The company’s management will host a conference call and webcast today at 1:30 p.m. PT/4:30 p.m. ET, to discuss second quarter 2022 financial results and operational progress as well as to provide additional color on its restructuring and strategic actions.
Individuals interested in listening to the conference call may do so by dialing:
US domestic callers: (888) 346-3970
Outside US callers: (412) 902-4297
Live audio of the webcast will be available online from the Investor Relations page of the company’s website at Events & Presentations. The webcast will be archived and available on the Standard BioTools Investor Relations page at investors.fluidigm.com.
A reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release.
Our investor presentation including Supplemental Financial Information has been posted on our website concurrent with this release.
Statement Regarding Use of Non-GAAP Financial Information
Standard BioTools has presented certain financial information in accordance with U.S. GAAP and also on a non-GAAP basis for the three- and six-month periods ended June 30, 2022, and June 30, 2021. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Standard BioTools encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding operational and strategic plans, deployment of capital, our cash runway and sufficiency of cash resources, margin expectations, potential M&A activity, and expectations with respect to our restructuring plans (including expense reduction activities involving potential subleasing and talent relocation plans, modifications to the scope of the company’s microfluidics and mass cytometry franchises and discontinuing of certain product lines). Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks that we may not realize expected cost savings from the restructuring, including the anticipated decrease in operational expenses, at the levels we expect; possible restructuring and transition-related disruption, including through the loss of customers, suppliers and employees and adverse impacts on our development activities and results of operation; restructuring activities, including our ability to execute subleasing plans, customer and employee relations, management distraction and reduced operating resources; internal and external costs required for ongoing and planned activities may be higher than expected which may cause us to use cash more quickly than we expect or change or curtail some of our plans or both; our expectations as to expenses, cash usage and cash needs may prove not to be correct for other reasons such as changes in plans or actual events being different than our assumptions; risks related to the adverse effects of the COVID-19 pandemic on our business and operating results; changes in Standard BioTools’ business or external market conditions; customers and prospective customers continuing to curtail or suspend activities utilizing our products due to the COVID-19 pandemic; our ability and/or the ability of the research institutions utilizing our products and technology to obtain and maintain Emergency Use Authorization from the FDA and any other requisite authorizations or approvals to use our products and technology for diagnostic testing purposes; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; interruptions or delays in the supply of components or materials for, or manufacturing of, Standard BioTools products; reliance on sales of capital equipment for a significant proportion of revenues in each quarter; seasonal variations in customer operations; unanticipated increases in costs or expenses; uncertainties in contractual relationships; reductions in research and development spending or changes in budget priorities by customers; Standard BioTools research and development and distribution plans and capabilities; potential product performance and quality issues; risks associated with international operations; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Standard BioTools’ business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2021, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Standard BioTools disclaims any obligation to update these forward-looking statements except as may be required by law.
About Standard BioTools Inc.
Standard BioTools Inc. (Nasdaq:LAB), previously known as Fluidigm Corporation, is driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health. Standard BioTools has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology, and immunotherapy. Learn more at www.standardbiotools.com or connect with us on Twitter®, Facebook®, LinkedIn, and YouTube™. Standard BioTools, the Standard BioTools logo, Fluidigm, the Fluidigm logo, and “Unleashing tools to accelerate breakthroughs in human health” are trademarks and/or registered trademarks of Standard BioTools Inc. or its affiliates in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Standard BioTools products are provided for Research Use Only. Not for use in diagnostic procedures.
Available Information
Standard BioTools uses its website (standardbio.com), investor site (investors.standardbiotools.com), corporate Twitter account (@Standard_BioT), Facebook page (facebook.com/StandardBioT), and LinkedIn page (linkedin.com/company/standard-biotools) as channels of distribution of information about its products, its planned financial and other announcements, its attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and Standard BioTools may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Standard BioTools’ website and its social media accounts in addition to following its press releases, SEC filings, public conference calls, and webcasts.
Investors:
Peter DeNardo
415 389 6400
ir@standardbio.com
| STANDARD BIOTOOLS INC. | ||||||||||||||||
| (formerly known as FLUIDIGM CORPORATION) | ||||||||||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Revenue | ||||||||||||||||
| Product revenue | $ | 12,219 | $ | 22,627 | $ | 32,223 | $ | 47,355 | ||||||||
| Service revenue | 5,806 | 6,627 | 11,950 | 12,913 | ||||||||||||
| Product and service revenue | 18,025 | 29,254 | 44,173 | 60,268 | ||||||||||||
| Other revenue (1) | 752 | 1,764 | 1,108 | 3,544 | ||||||||||||
| Total revenue | 18,777 | 31,018 | 45,281 | 63,812 | ||||||||||||
| Costs and expenses | ||||||||||||||||
| Cost of product revenue | 12,738 | 12,730 | 25,077 | 24,393 | ||||||||||||
| Cost of service revenue | 1,612 | 1,867 | 3,540 | 3,957 | ||||||||||||
| Cost of product and service revenue | 14,350 | 14,597 | 28,617 | 28,350 | ||||||||||||
| Research and development | 12,606 | 9,441 | 21,471 | 20,194 | ||||||||||||
| Selling, general and administrative | 30,384 | 24,248 | 61,259 | 51,856 | ||||||||||||
| Total costs and expenses | 57,340 | 48,286 | 111,347 | 100,400 | ||||||||||||
| Loss from operations | (38,563 | ) | (17,268 | ) | (66,066 | ) | (36,588 | ) | ||||||||
| Interest expense | (1,062 | ) | (896 | ) | (2,092 | ) | (1,783 | ) | ||||||||
| Loss on forward sale of Series B Preferred Stock | (22,289 | ) | — | (60,081 | ) | — | ||||||||||
| Loss on bridge loans | (3,064 | ) | — | (13,719 | ) | — | ||||||||||
| Other income (expense), net | (174 | ) | 504 | (56 | ) | 219 | ||||||||||
| Loss before income taxes | (65,152 | ) | (17,660 | ) | (142,014 | ) | (38,152 | ) | ||||||||
| Income tax benefit | 1,613 | 517 | 2,187 | 2,188 | ||||||||||||
| Net loss | $ | (63,539 | ) | $ | (17,143 | ) | $ | (139,827 | ) | $ | (35,964 | ) | ||||
| Net loss per share, basic and diluted | $ | (0.82 | ) | $ | (0.23 | ) | $ | (1.81 | ) | $ | (0.48 | ) | ||||
| Shares used in computing net loss per share, basic and diluted | 77,821 | 75,452 | 77,430 | 75,084 | ||||||||||||
| Note: (1) Other revenue includes product development, license and grant revenue. | ||||||||||||||||
| STANDARD BIOTOOLS INC. | |||||||
| (formerly known as FLUIDIGM CORPORATION) | |||||||
| CONDENSED CONSOLIDATED BALANCE SHEETS | |||||||
| (In thousands) | |||||||
| (Unaudited) | |||||||
| June 30, 2022 | December 31, 2021 (1) | ||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents (2) | $ | 74,361 | $ | 28,451 | |||
| Short-term investments (2) | 136,850 | — | |||||
| Accounts receivable, net | 10,937 | 18,320 | |||||
| Inventories, net | 22,791 | 20,825 | |||||
| Prepaid expenses and other current assets | 5,938 | 4,470 | |||||
| Total current assets | 250,877 | 72,066 | |||||
| Property and equipment, net | 27,275 | 28,034 | |||||
| Operating lease right-of-use asset, net | 35,412 | 37,119 | |||||
| Other non-current assets | 3,158 | 3,689 | |||||
| Developed technology, net | 18,200 | 27,927 | |||||
| Goodwill | 106,200 | 106,379 | |||||
| Total assets | $ | 441,122 | $ | 275,214 | |||
| LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 9,016 | $ | 10,602 | |||
| Accrued compensation and related benefits | 8,576 | 4,920 | |||||
| Operating lease liabilities, current | 3,293 | 3,053 | |||||
| Deferred revenue, current | 11,409 | 11,947 | |||||
| Deferred grant income, current | 3,729 | 3,535 | |||||
| Other accrued liabilities | 6,747 | 8,673 | |||||
| Advances under revolving credit agreement, current | — | 6,838 | |||||
| Total current liabilities | 42,770 | 49,568 | |||||
| Convertible notes, net | 54,384 | 54,160 | |||||
| Term loan, net | 10,162 | 10,049 | |||||
| Deferred tax liability | 1,651 | 4,329 | |||||
| Operating lease liabilities, non-current | 35,732 | 37,548 | |||||
| Deferred revenue, non-current | 5,064 | 5,966 | |||||
| Deferred grant income, non-current | 16,263 | 18,116 | |||||
| Other non-current liabilities | 1,297 | 882 | |||||
| Total liabilities | 167,323 | 180,618 | |||||
| Redeemable preferred stock | 311,253 | — | |||||
| Total stockholders’ equity (deficit) | (37,454 | ) | 94,596 | ||||
| Total liabilities, mezzanine equity and stockholders’ equity (deficit) | $ | 441,122 | $ | 275,214 | |||
| Notes: | |||||||
| (1) Derived from audited consolidated financial statements | |||||||
| (2) Cash and cash equivalents and available for sale securities consist of: | |||||||
| Cash and cash equivalents | $ | 74,361 | $ | 28,451 | |||
| Short-term investments | 136,850 | — | |||||
| Total cash, cash equivalents and available for sale securities | $ | 211,211 | $ | 28,451 | |||
| STANDARD BIOTOOLS INC. | ||||||||
| (formerly known as FLUIDIGM CORPORATION) | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (In thousands) | ||||||||
| (Unaudited) | ||||||||
| Six Months Ended June 30, | ||||||||
| 2022 | 2021 | |||||||
| Operating activities | ||||||||
| Net loss | $ | (139,827 | ) | $ | (35,964 | ) | ||
| Loss on forward sale of Series B Preferred Stock | 60,081 | — | ||||||
| Loss on bridge loans | 13,719 | — | ||||||
| Stock-based compensation expense | 8,705 | 7,418 | ||||||
| Amortization of developed technology | 5,928 | 5,965 | ||||||
| Depreciation and amortization | 1,878 | 1,851 | ||||||
| Provision for excess and obsolete inventory | 4,597 | 1,248 | ||||||
| Impairment of intangible | 3,526 | — | ||||||
| Other non-cash items | 599 | 539 | ||||||
| Changes in assets and liabilities, net | (4,784 | ) | (8,622 | ) | ||||
| Net cash used in operating activities | (45,578 | ) | (27,565 | ) | ||||
| Investing activities | ||||||||
| Purchases of investments | (137,302 | ) | — | |||||
| Proceeds from NIH Contract | — | 2,000 | ||||||
| Purchases of property and equipment | (1,806 | ) | (11,095 | ) | ||||
| Net cash used in investing activities | (139,108 | ) | (9,095 | ) | ||||
| Financing activities | ||||||||
| Proceeds from bridge loans | 25,000 | — | ||||||
| Proceeds from issuance of Series B Preferred Stock | 225,000 | — | ||||||
| Repayment of advances under credit agreement | (6,838 | ) | — | |||||
| Payment of equity issuance costs | (12,547 | ) | — | |||||
| Repayment of long-term debt | — | (501 | ) | |||||
| Proceeds from (payments for) employee equity programs, net | 418 | (658 | ) | |||||
| Net cash provided by (used in) financing activities | 231,033 | (1,159 | ) | |||||
| Effect of foreign exchange rate fluctuations on cash and cash equivalents | (437 | ) | 162 | |||||
| Net increase (decrease) in cash, cash equivalents and restricted cash | 45,910 | (37,657 | ) | |||||
| Cash, cash equivalents and restricted cash at beginning of period | 29,467 | 69,536 | ||||||
| Cash, cash equivalents and restricted cash at end of period | $ | 75,377 | $ | 31,879 | ||||
| Cash and cash equivalents, and available for sale securities consist of: | ||||||||
| Cash and cash equivalents | $ | 74,361 | $ | 30,863 | ||||
| Short-term investments | 136,850 | — | ||||||
| Total cash and cash equivalents, and available for sale securities | $ | 211,211 | $ | 30,863 | ||||
| STANDARD BIOTOOLS INC. | ||||||||||||||||
| (formerly known as FLUIDIGM CORPORATION) | ||||||||||||||||
| RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION | ||||||||||||||||
| (In thousands, except per share amounts) | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET LOSS | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Net loss (GAAP) | $ | (63,539 | ) | $ | (17,143 | ) | $ | (139,827 | ) | $ | (35,964 | ) | ||||
| Loss on forward sale of Series B Preferred Stock | 22,289 | — | 60,081 | — | ||||||||||||
| Loss on bridge loans | 3,064 | — | 13,719 | — | ||||||||||||
| Stock-based compensation expense | 4,663 | 3,741 | 8,705 | 7,418 | ||||||||||||
| Amortization of developed technology (a) | 2,961 | 2,982 | 5,928 | 5,965 | ||||||||||||
| Depreciation and amortization | 875 | 917 | 1,878 | 1,851 | ||||||||||||
| Interest expense (b) | 1,062 | 896 | 2,092 | 1,783 | ||||||||||||
| Impairment of intangible (c) | 3,526 | — | 3,526 | — | ||||||||||||
| Loss on disposal of property and equipment | 6 | 1 | 15 | 1 | ||||||||||||
| Loss on extinguishment of debt | — | — | — | 9 | ||||||||||||
| Benefit from acquisition related income taxes (d) | (742 | ) | (742 | ) | (1,484 | ) | (1,484 | ) | ||||||||
| Net loss (Non-GAAP) | $ | (25,835 | ) | $ | (9,348 | ) | $ | (45,367 | ) | $ | (20,421 | ) | ||||
| Shares used in net loss per share calculation - | ||||||||||||||||
| basic and diluted (GAAP and Non-GAAP) | 77,821 | 75,452 | 77,430 | 75,084 | ||||||||||||
| Net loss per share - basic and diluted (GAAP) | $ | (0.82 | ) | $ | (0.23 | ) | $ | (1.81 | ) | $ | (0.48 | ) | ||||
| Net loss per share - basic and diluted (Non-GAAP) | $ | (0.33 | ) | $ | (0.12 | ) | $ | (0.59 | ) | $ | (0.27 | ) | ||||
| ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP PRODUCT AND SERVICE MARGIN | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Product and service gross profit (GAAP) | $ | 3,675 | $ | 14,657 | $ | 15,556 | $ | 31,918 | ||||||||
| Amortization of developed technology (a) | 2,641 | 2,800 | 5,608 | 5,600 | ||||||||||||
| Depreciation and amortization (e) | 319 | 393 | 634 | 813 | ||||||||||||
| Stock-based compensation expense (e) | 164 | 128 | 305 | 226 | ||||||||||||
| Product and service gross profit (Non-GAAP) | $ | 6,799 | $ | 17,978 | $ | 22,103 | $ | 38,557 | ||||||||
| Product and service margin (GAAP) | 20.4 | % | 50.1 | % | 35.2 | % | 53.0 | % | ||||||||
| Product and service margin (Non-GAAP) | 37.7 | % | 61.5 | % | 50.0 | % | 64.0 | % | ||||||||
| ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP OPERATING EXPENSES | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Operating expenses (GAAP) | $ | 42,990 | $ | 33,689 | $ | 82,730 | $ | 72,050 | ||||||||
| Stock-based compensation expense (f) | (4,499 | ) | (3,613 | ) | (8,400 | ) | (7,192 | ) | ||||||||
| Depreciation and amortization (f) | (877 | ) | (707 | ) | (1,565 | ) | (1,404 | ) | ||||||||
| Impairment of intangible (c) | (3,526 | ) | — | (3,526 | ) | — | ||||||||||
| Loss on disposal of property and equipment (f) | (6 | ) | (1 | ) | (15 | ) | (1 | ) | ||||||||
| Operating expenses (Non-GAAP) | $ | 34,082 | $ | 29,368 | $ | 69,224 | $ | 63,453 | ||||||||
| ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP LOSS FROM OPERATIONS | ||||||||||||||||
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2022 | 2021 | 2022 | 2021 | |||||||||||||
| Loss from operations (GAAP) | $ | (38,563 | ) | $ | (17,268 | ) | $ | (66,066 | ) | $ | (36,588 | ) | ||||
| Stock-based compensation expense | 4,663 | 3,741 | 8,705 | 7,418 | ||||||||||||
| Amortization of developed technology (a) | 2,961 | 2,982 | 5,928 | 5,965 | ||||||||||||
| Depreciation and amortization (f) | 875 | 917 | 1,878 | 1,851 | ||||||||||||
| Impairment of intangible (c) | 3,526 | — | 3,526 | — | ||||||||||||
| Loss on disposal of property and equipment (f) | 6 | 1 | 15 | 1 | ||||||||||||
| Loss from operations (Non-GAAP) | $ | (26,532 | ) | $ | (9,627 | ) | $ | (46,014 | ) | $ | (21,353 | ) | ||||
| (a) Represents amortization of developed technology in connection with the DVS and InstruNor acquisitions | ||||||||||||||||
| (b) Represents interest expense, primarily on convertible debt and the term loan | ||||||||||||||||
| (c) Represents impairment of intangible no longer used in our product lines | ||||||||||||||||
| (d) Represents the tax impact on the purchase of intangible assets in connection with the DVS acquisition | ||||||||||||||||
| (e) Represents expense associated with cost of product revenue | ||||||||||||||||
| (f) Represents expense associated with research and development, and selling, general and administrative activities | ||||||||||||||||